Studying synergistic anticancer effects of repurposed AT1B losartan with antidiabetics metformin, rosiglitazone in triple-negative breast cancer cells - PubMed
3 hours ago
- #triple-negative-breast-cancer
- #synergistic-effects
- #drug-repurposing
- The study investigates repurposing losartan, metformin, and rosiglitazone for triple-negative breast cancer (TNBC) therapy.
- Cytotoxicity assays show IC50 values: losartan at 1231 μM, metformin at 30.37 μM, and rosiglitazone at 267.1 μM.
- Losartan combined with metformin shows synergistic effects, with a 1.6-fold potency increase at a 1:1 ratio, enhancing cell growth inhibition below 1280 μM.
- Combining losartan with rosiglitazone improves efficacy at higher doses (≥320 μM), indicated by right-shifted dose-response curves and increased maximal responses.
- In MDA-MB-231 cells, losartan and metformin combination yields strong synergy with high dose reduction indices (DRIs): 21.92 for losartan and 17.247 for metformin.
- At lower doses, the combination of losartan and rosiglitazone does not achieve additional synergistic effects, limiting its applicability in concurrent administration.